Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G.

Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6. Epub 2012 Dec 1.

2.

Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.

Chen N, Wen L, Lau H, Surapaneni S, Kumar G.

Cancer Chemother Pharmacol. 2012 Mar;69(3):789-97. doi: 10.1007/s00280-011-1760-3. Epub 2011 Oct 29.

3.

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, Gu Z, Heller D, Feng H, Surapaneni S, Laskin O, Wu A.

Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23.

4.

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.

Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23.

5.

Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.

Wright LC, Maia J, Loureiro AI, Almeida L, Soares-Da-Silva P.

Drug Metab Lett. 2010 Aug;4(3):149-62.

PMID:
20642448
6.

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.

Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:60-7. doi: 10.1111/j.1365-2125.2008.03137.x.

8.

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA.

Drug Metab Dispos. 2007 Apr;35(4):533-8. Epub 2007 Jan 12.

9.

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.

Tiseo PJ, Perdomo CA, Friedhoff LT.

Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:19-24.

10.

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, Giles P.

Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011. Epub 2011 Dec 28.

PMID:
22206795
11.

Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.

Prakash C, Cui D, Baxter JG, Bright GM, Miceli J, Wilner K.

Drug Metab Dispos. 1998 May;26(5):448-56.

12.

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro.

Gschwind HP, Glaenzel U, Waldmeier F, Wirz B, Sabia HD, Picard F, Weiss HM, Choi L, Swart PJ, Vasudevan A, Azria M.

Eur J Pharm Sci. 2012 Aug 30;47(1):44-55. doi: 10.1016/j.ejps.2012.04.023. Epub 2012 May 8.

PMID:
22579664
13.

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2012 Jul;40(7):1345-56. doi: 10.1124/dmd.112.045450. Epub 2012 Apr 10.

14.

Pharmacokinetics and metabolism of nateglinide in humans.

Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):415-21.

15.
16.

Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

Zollinger M, Lozac'h F, Hurh E, Emotte C, Bauly H, Swart P.

Cancer Chemother Pharmacol. 2014 Jul;74(1):63-75. doi: 10.1007/s00280-014-2468-y. Epub 2014 May 10.

PMID:
24817600
17.

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.

He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D.

Drug Metab Dispos. 2009 Mar;37(3):536-44. doi: 10.1124/dmd.108.023010. Epub 2008 Dec 15.

18.

Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.

James A, Blumenstein L, Glaenzel U, Jin Y, Demailly A, Jakab A, Hansen R, Hazell K, Mehta A, Trandafir L, Swart P.

Cancer Chemother Pharmacol. 2015 Oct;76(4):751-60. doi: 10.1007/s00280-015-2842-4. Epub 2015 Aug 8.

PMID:
26254025
19.

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.

Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258. Epub 2012 Jul 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk